[Anti-cancer monoclonal antibody].
Sasaki
Shigeru
S
First Department of Internal Medicine, Sapporo Medical University.
Ishida
Tadao
T
Tsujisaki
Masayuki
M
Imai
Kohzoh
K
D000074323:Alemtuzumab; D000617:Aminoglycosides / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000068258:Bevacizumab; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D000079982:Gemtuzumab; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D000068878:Trastuzumab; D016896:Treatment Outcome
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; C400149:Edrecolomab; D000068258:Bevacizumab; D000074323:Alemtuzumab; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D000079982:Gemtuzumab; C119496:tositumomab I-131; D000068878:Trastuzumab; D000068818:Cetuximab